Search Results - "LONG, Georgina V"

Learning from clinical trials of neoadjuvant checkpoint blockade by Versluis, Judith M., Long, Georgina V., Blank, Christian U.

“…Neoadjuvant checkpoint inhibition, in which the therapy is administered before surgery, is a promising new approach to managing bulky but resectable melanoma,…”
Get full text

Targeted agents and immunotherapies: optimizing outcomes in melanoma by Luke, Jason J., Flaherty, Keith T., Ribas, Antoni, Long, Georgina V.

“…Key Points Clinical therapeutics for advanced-stage melanoma have improved dramatically with the development of BRAF and MEK inhibitors, cytotoxic…”
Get full text

Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma by Gide, Tuba N, Wilmott, James S, Scolyer, Richard A, Long, Georgina V

“…Immune checkpoint inhibitors have revolutionized the treatment of patients with advanced-stage metastatic melanoma, as well as patients with many other solid…”
Get full text

Systemic treatment for BRAF -mutant melanoma: where do we go next? by Menzies, Alexander M, MBBS, Long, Georgina V, Prof

“…Summary After decades of treatment failure for metastatic melanoma, the development of BRAF inhibitors was highly anticipated to dramatically improve outcomes…”
Get full text

Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma by MENZIES, Alexander M, LONG, Georgina V

“…Dabrafenib and trametinib were approved for use as monotherapies in BRAF-mutant metastatic melanoma by the U.S. Food and Drug Administration (FDA) in 2013, and…”
Get full text

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study by Robert, Caroline, Prof, Ribas, Antoni, Prof, Schachter, Jacob, Prof, Arance, Ana, MD, Grob, Jean-Jacques, Prof, Mortier, Laurent, Prof, Daud, Adil, Prof, Carlino, Matteo S, MB, McNeil, Catriona M, MD, Lotem, Michal, Prof, Larkin, James M G, Prof, Lorigan, Paul, Prof, Neyns, Bart, Prof, Blank, Christian U, Prof, Petrella, Teresa M, MD, Hamid, Omid, MD, Su, Shu-Chih, PhD, Krepler, Clemens, MD, Ibrahim, Nageatte, MD, Long, Georgina V, Prof

“…SummaryBackgroundPembrolizumab improved progression-free survival and overall survival versus ipilimumab in patients with advanced melanoma and is now a…”
Get full text

Resistance to PD1/PDL1 checkpoint inhibition by O’Donnell, Jake S, Long, Georgina V, Scolyer, Richard A, W. L. Teng, Michele, Smyth, Mark J

“…Highlights • Resistance to anti-PD1 therapy affects up to ∼70% of patients treated. • Resistance can be primary or acquired. • Tumor intrinsic mechanisms that…”
Get full text

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study by Long, Georgina V, Prof, Dummer, Reinhard, Prof, Hamid, Omid, MD, Gajewski, Thomas F, Prof, Caglevic, Christian, MD, Dalle, Stephane, Prof, Arance, Ana, MD, Carlino, Matteo S, PhD, Grob, Jean-Jacques, Prof, Kim, Tae Min, Prof, Demidov, Lev, Prof, Robert, Caroline, Prof, Larkin, James, Prof, Anderson, James R, PhD, Maleski, Janet, BSN, Jones, Mark, MD, Diede, Scott J, MD, Mitchell, Tara C, MD

“…SummaryBackgroundImmunotherapy combination treatments can improve patient outcomes. Epacadostat, an IDO1 selective inhibitor, and pembrolizumab, a PD-1…”
Get full text

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy by Gide, Tuba N., Quek, Camelia, Menzies, Alexander M., Tasker, Annie T., Shang, Ping, Holst, Jeff, Madore, Jason, Lim, Su Yin, Velickovic, Rebecca, Wongchenko, Matthew, Yan, Yibing, Lo, Serigne, Carlino, Matteo S., Guminski, Alexander, Saw, Robyn P.M., Pang, Angel, McGuire, Helen M., Palendira, Umaimainthan, Thompson, John F., Rizos, Helen, Silva, Ines Pires da, Batten, Marcel, Scolyer, Richard A., Long, Georgina V., Wilmott, James S.

“…Cancer immunotherapies provide survival benefits in responding patients, but many patients fail to respond. Identifying the biology of treatment response and…”
Get full text

Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade by House, Imran G, Savas, Peter, Lai, Junyun, Chen, Amanda X Y, Oliver, Amanda J, Teo, Zhi L, Todd, Kirsten L, Henderson, Melissa A, Giuffrida, Lauren, Petley, Emma V, Sek, Kevin, Mardiana, Sherly, Gide, Tuba N, Quek, Camelia, Scolyer, Richard A, Long, Georgina V, Wilmott, James S, Loi, Sherene, Darcy, Phillip K, Beavis, Paul A

“…Response rates to immune checkpoint blockade (ICB; anti-PD-1/anti-CTLA-4) correlate with the extent of tumor immune infiltrate, but the mechanisms underlying…”
Get full text

Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy by Lim, Su Y, Lee, Jenny H, Gide, Tuba N, Menzies, Alexander M, Guminski, Alexander, Carlino, Matteo S, Breen, Edmond J, Yang, Jean Y H, Ghazanfar, Shila, Kefford, Richard F, Scolyer, Richard A, Long, Georgina V, Rizos, Helen

“…Combination PD-1 and CTLA-4 inhibitor therapy has dramatically improved the survival of patients with advanced melanoma but is also associated with significant…”
Get full text

Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment by Muir, Christopher A, Clifton-Bligh, Roderick J, Long, Georgina V, Scolyer, Richard A, Lo, Serigne N, Carlino, Matteo S, Tsang, Venessa H M, Menzies, Alexander M

“…Abstract Context Thyroid dysfunction occurs commonly following immune checkpoint inhibition. The etiology of thyroid immune-related adverse events (irAEs)…”
Get full text

Cutaneous toxicities of RAF inhibitors by Anforth, Rachael, BMed, Fernandez-Peñas, Pablo, PhD, Long, Georgina V, Dr

“…Summary The RAF inhibitors vemurafenib and dabrafenib are emerging as the standard of care for Val600 BRAF -mutant metastatic melanoma. These drugs have shown…”
Get full text

Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition by Lee, Jenny H., Shklovskaya, Elena, Lim, Su Yin, Carlino, Matteo S., Menzies, Alexander M., Stewart, Ashleigh, Pedersen, Bernadette, Irvine, Malama, Alavi, Sara, Yang, Jean Y. H., Strbenac, Dario, Saw, Robyn P. M., Thompson, John F., Wilmott, James S., Scolyer, Richard A., Long, Georgina V., Kefford, Richard F., Rizos, Helen

“…Transcriptomic signatures designed to predict melanoma patient responses to PD-1 blockade have been reported but rarely validated. We now show that…”
Get full text

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials by Long, Georgina V, Prof, Grob, Jean-Jacques, Prof, Nathan, Paul, MD, Ribas, Antoni, Prof, Robert, Caroline, MD, Schadendorf, Dirk, Prof, Lane, Stephen R, MSc, Mak, Carmen, PhD, Legenne, Philippe, MD, Flaherty, Keith T, Prof, Davies, Michael A, MD

“…Summary Background Dabrafenib plus trametinib treatment provides significant benefits over BRAF-inhibitor monotherapy in patients with BRAFV600E -mutant or…”
Get full text

Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study by Meric-Bernstam, Funda, Sweis, Randy F, Kasper, Stefan, Hamid, Omid, Bhatia, Shailender, Dummer, Reinhard, Stradella, Agostina, Long, Georgina V, Spreafico, Anna, Shimizu, Toshio, Steeghs, Neeltje, Luke, Jason J, McWhirter, Sarah M, Müller, Thomas, Nair, Nitya, Lewis, Nancy, Chen, Xinhui, Bean, Andrew, Kattenhorn, Lisa, Pelletier, Marc, Sandhu, Shahneen

“…The stimulator of IFN genes (STING) is a transmembrane protein that plays a role in the immune response to tumors. Single-agent STING agonist MIW815 (ADU-S100)…”
Get full text

High response rate to PD-1 blockade in desmoplastic melanomas by Eroglu, Zeynep, Zaretsky, Jesse M., Hu-Lieskovan, Siwen, Kim, Dae Won, Algazi, Alain, Johnson, Douglas B., Liniker, Elizabeth, Ben Kong, Munhoz, Rodrigo, Rapisuwon, Suthee, Gherardini, Pier Federico, Chmielowski, Bartosz, Wang, Xiaoyan, Shintaku, I. Peter, Wei, Cody, Sosman, Jeffrey A., Joseph, Richard W., Postow, Michael A., Carlino, Matteo S., Hwu, Wen-Jen, Scolyer, Richard A., Messina, Jane, Cochran, Alistair J., Long, Georgina V., Ribas, Antoni

“…Immune checkpoint blockade with anti-PD-1 or anti-PD-L1 agents produces a high response rate in patients with desmoplastic melanoma. Highly sensitive skin…”
Get full text

Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next? by Welsh, Sarah J, Rizos, Helen, Scolyer, Richard A, Long, Georgina V

“…Abstract Treatment of BRAF-mutant metastatic melanoma with mitogen-activated protein kinase (MAPK) pathway targeted therapies (BRAF/MEK inhibitors) and immune…”
Get full text

BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact by RIZOS, Helen, MENZIES, Alexander M, HOWIE, Julie, SAW, Robyn, THOMPSON, John F, KEFFORD, Richard F, SCOLYER, Richard A, LONG, Georgina V, PUPO, Gulietta M, CARLINO, Matteo S, FUNG, Carina, HYMAN, Jessica, HAYDU, Lauren E, MIJATOV, Branka, BECKER, Therese M, BOYD, Suzanah C

“…Multiple BRAF inhibitor resistance mechanisms have been described, however, their relative frequency, clinical correlates, and effect on subsequent therapy…”
Get full text

Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial by Dummer, Reinhard, Prof, Schadendorf, Dirk, Prof, Ascierto, Paolo A, MD, Arance, Ana, MD, Dutriaux, Caroline, MD, Di Giacomo, Anna Maria, MD, Rutkowski, Piotr, Prof, Del Vecchio, Michele, MD, Gutzmer, Ralf, Prof, Mandala, Mario, MD, Thomas, Luc, Prof, Demidov, Lev, Prof, Garbe, Claus, Prof, Hogg, David, MD, Liszkay, Gabriella, Prof, Queirolo, Paola, MD, Wasserman, Ernesto, MD, Ford, James, MS, Weill, Marine, MSc, Sirulnik, L Andres, MD, Jehl, Valentine, MSc, Bozón, Viviana, MD, Long, Georgina V, Prof, Flaherty, Keith, MD

“…Summary Background There are no established therapies specific for NRAS -mutant melanoma despite the emergence of immunotherapy. We aimed to assess the…”
Get full text